Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.

Wan-Yu ChuKim V AnninkA Laura NijstadChristian A MaiwaldMichael SchrothLoubna El BakkaliFrank van BelManon J N L BendersMirjam M van WeissenbruchAnja HagenAxel R FranzThomas P C DorloKarel AllegaertAlwin D R Huitemanull null

Published in: Clinical pharmacokinetics (2021)

The PK and PD of allopurinol, oxypurinol, hypoxanthine, xanthine, and uric acid in neonates with HIE were described. The dosing regimen applied in the ALBINO trial leads to the targeted XO inhibition in neonates treated with or without TH.

Keyphrases

uric acid
metabolic syndrome
low birth weight
preterm infants
study protocol
clinical trial
early onset
cancer therapy
preterm birth
phase ii
drug delivery